Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Healthcare Opportunities Fund offers a compelling way to play the healthcare sector. Read here for an analysis of THQ CEF.

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Eli Lilly & Co ( ($LLY) ) has risen by 10.63%. Read on to learn why. Eli Lilly & Co has seen a notable increase in its stock price, rising ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent ...

The medical world relies on horseshoe crab blood in the production of vaccines and equipment. A synthetic is available, but ...